Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Renata Duchnowska; Aleksandra Grela-Wojewoda; Karolina Winsko-Szczęsnowicz; Iwona Danielewicz; Tomasz Lewandowski; Joanna Kiszka; Barbara Radecka; Ewa Kalinka‐Warzocha; Bartosz Kamil Sobocki; Aleksandra Łacko; A Balata; Rodryg Ramlau; Paulina Myśliwiec; Piotr Lipiec; Michał Jurczyk; Grzegorz Kade; Ewa Kustra; Jacek Jassem

doi:10.1016/j.breast.2025.104665

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Duchnowska et al. (2025) studied this question.

synapsesocial.com/papers/694039872d562116f290ad15 https://doi.org/10.1016/j.breast.2025.104665

View Full Paper

Ask AI

Bookmark

Share

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Ask about this paper

Abstract

Discussion

Cite This Study

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading